Apellis Pharmaceuticals Inc (APLS)

06:24 AM

What analysts say about Apellis Pharmaceuticals Inc. stockSky-high return potential - Autocar Professional

06:24 AM

Jul 24, 2025

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025 - GuruFocus

Jul 24, 2025

Jul 24, 2025

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results - The Manila Times

Jul 24, 2025

Jul 23, 2025

Is Apellis Pharmaceuticals Inc. a good long term investmentDynamic investment growth - jammulinksnews.com

Jul 23, 2025

Jul 23, 2025

Complement 3 Glomerulopathy Market Expected to Experience Major Growth by 2034, According to DelveInsight | NovelMed Therapeutics, Apellis Pharma, Novartis, Amyndas Pharma - Barchart.com

Jul 23, 2025

Jul 23, 2025

Apellis Pharmaceuticals Inc. Stock Analysis and ForecastOutstanding trading profits - jammulinksnews.com

Jul 23, 2025

Jul 22, 2025

What drives Apellis Pharmaceuticals Inc. stock priceExceptional market performance - jammulinksnews.com

Jul 22, 2025

Jul 21, 2025

Intermediate Age-Related Macular Degeneration Market Research 2025-2035 Featuring Novartis, Allegro Ophthalmics, and Apellis PharmaceuticalsResearchAndMarkets.com - FinancialContent

Jul 21, 2025

Jul 18, 2025

Baird Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Raises Target Price to $50 - 富途牛牛

Jul 18, 2025

Jul 18, 2025

Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings) - Benzinga

Jul 18, 2025

Jul 18, 2025

Fierce Biotech Layoff Tracker 2025: Sail shrinks crew again; Sarepta lays off 500 staffers - Fierce Biotech

Jul 18, 2025

Jul 16, 2025

APLS Stock Update: B of A Securities Raises Price Target | APLS - GuruFocus

Jul 16, 2025

Jul 15, 2025

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting - The Manila Times

Jul 15, 2025

Jul 15, 2025

Apellis Reveals 48-Month SYFOVRE Data: 5 Key Studies Show Promise for Geographic Atrophy Treatment - Stock Titan

Jul 15, 2025

Jul 14, 2025

H.C. Wainwright reiterates Buy rating on Apellis Pharmaceuticals stock By Investing.com - Investing.com Canada

Jul 14, 2025

Jul 14, 2025

How the (APLS) price action is used to our Advantage - news.stocktradersdaily.com

Jul 14, 2025

Jul 11, 2025

Apellis Pharmaceuticals (APLS) Receives a Buy from Cantor Fitzgerald - The Globe and Mail

Jul 11, 2025

Jul 11, 2025

Apellis stock holds Outperform rating at William Blair amid Izervay competition - Investing.com Canada

Jul 11, 2025

Jul 10, 2025

Apellis Sells Aspaveli Ex-US Royalties to Sobi for Up to $300M - MSN

Jul 10, 2025

Jul 10, 2025

Cantor Fitzgerald reiterates Apellis stock Overweight rating with $39 target By Investing.com - Investing.com Canada

Jul 10, 2025

Jul 10, 2025

Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Charles River Labs (CRL) - The Globe and Mail

Jul 10, 2025

Jul 08, 2025

16 Most Promising Stocks According to Wall Street Analysts - Insider Monkey

Jul 08, 2025

Jul 07, 2025

Morgan Stanley Raises PT on Apellis Pharmaceuticals (APLS) to $26, Keeps a Hold Rating - MSN

Jul 07, 2025

Jul 07, 2025

Morgan Stanley raised the Target Price of Apellis Pharmaceuticals (APLS.US) to $26 and maintained a "Hold" rating. - 富途牛牛

Jul 07, 2025

Jul 06, 2025

Apellis stock surges after Sobi $300 million royalty deal - MSN

Jul 06, 2025

Jul 05, 2025

Apellis Pharmaceuticals, Inc. (APLS) Insider Activity Signals Possible Market Mispricing - MSN

Jul 05, 2025

Jul 03, 2025

SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Jul 03, 2025

Jul 03, 2025

WilmerHale Advises Apellis Pharmaceuticals in Purchase Agreement with Sobi - WilmerHale

Jul 03, 2025

Jul 03, 2025

(APLS) Trading Advice - news.stocktradersdaily.com

Jul 03, 2025

Jul 03, 2025

Apellis signs royalty purchase deal with Sobi for Aspaveli - MSN

Jul 03, 2025

Jul 03, 2025

Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli - MSN

Jul 03, 2025

Jul 03, 2025

Analysts Offer Insights on Healthcare Companies: BeiGene (ONC), Apellis Pharmaceuticals (APLS) and Pliant Therapeutics (PLRX) - The Globe and Mail

Jul 03, 2025

Jul 02, 2025

What 13 Analyst Ratings Have To Say About Apellis Pharmaceuticals - Nasdaq

Jul 02, 2025

Jul 02, 2025

Mizuho maintains Neutral rating on Apellis stock amid royalty deal with Sobi - Investing.com Canada

Jul 02, 2025